Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06524063Phase 1Not Yet Recruiting

Targeted Survivin DC Cell Injection for the Treatment of GBM

Role: lead

NCT02808416Phase 1Completed

Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

Role: collaborator

NCT02808364Phase 1Completed

Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)

Role: collaborator

NCT02709616Phase 1Completed

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Role: collaborator

All 4 trials loaded